Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 phase III clinical trials

Pediatrics

Volumn 138, Issue 2, 2016, Pages

  Moreira, Edson D ^a   Block, Stan L ^b   Ferris, Daron ^c   Giuliano, Anna R ^d   Iversen, Ole Erik ^e   Joura, Elmar A ^f   Kosalaraksa, Pope ^g   Schilling, Andrea ^h   Van Damme, Pierre ⁱ   Bornstein, Jacob ^j   Bosch, F Xavier ^k   Pils, Sophie ^f   Cuzick, Jack ^l   Garland, Suzanne M ^m   Huh, Warner ⁿ   Kjaer, Susanne K ^o   Qi, Hong ^p   Hyatt, Donna ^p   Martin, Jason ^p   Moeller, Erin ^p   Ritter, Michael ^p   Baudin, Martine ^q   Luxembourg, Alain ^p   more..

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Kentucky Pediatric Research Institute   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF BERGEN   (Norway)

^f UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^g KHON KAEN UNIVERSITY   (Thailand)

^h UNIVERSIDAD DEL DESARROLLO   (Chile)

ⁱ UNIVERSITY OF ANTWERP   (Belgium)

^j BAR ILAN UNIVERSITY   (Israel)

^k CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^l QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^m UNIVERSITY OF MELBOURNE   (Australia)

ⁿ University of Alabama   (United States)

^o UNIVERSITY OF COPENHAGEN   (Denmark)

^p MERCK RESEARCH LABORATORIES   (United States)

^q SANOFI PASTEUR   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

9 VALENT HUMAN PAPILLOMAVIRUS VACCINE; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ALLERGY; ANAPHYLAXIS; APPENDICITIS; ARTHRALGIA; ARTICLE; BREAST DISEASE; CHILD; COMPLEX REGIONAL PAIN SYNDROME; CONGENITAL DISORDER; CONNECTIVE TISSUE DISEASE; CYST; DISEASE SEVERITY; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR DISEASE; ECTOPIC PREGNANCY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GENETIC DISORDER; HEADACHE; HEART DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPERSENSITIVITY; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJURY; INNER EAR DISEASE; KIDNEY DISEASE; LOW DRUG DOSE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); POLYP; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; PREGNANCY DISORDER; PREGNANCY OUTCOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; SARCOIDOSIS; SKIN DISEASE; SOFT TISSUE DISEASE; THORAX DISEASE; URINARY TRACT DISEASE; VACCINATION; VASCULAR DISEASE; EDEMA; ERYTHEMA; FOLLOW UP; IMMUNIZATION; META ANALYSIS; OUTCOME ASSESSMENT; PAIN; PREGNANCY; PREGNANCY COMPLICATIONS; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CLINICAL TRIALS, PHASE III AS TOPIC; EDEMA; ERYTHEMA; FEMALE; FEVER; FOLLOW-UP STUDIES; HEADACHE; HUMANS; IMMUNIZATION SCHEDULE; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PAIN; PAPILLOMAVIRUS VACCINES; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; YOUNG ADULT;

EID: 84982855434     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2015-4387     Document Type: Article

References (42)

1. de Sanjose S, Quint WG, Alemany L, et al; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study. Lancet Oncol. 2010;11(11):1048-1056
2. Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7(1):38
3. de Sanjosé S, Alemany L, Ordi J, et al; HPV VVAP study group. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer. 2013;49(16):3450-3461
4. Alemany L, Saunier M, Alvarado-Cabrero I, et al; HPV VVAP Study Group. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015;136(1):98-107
5. Alemany L, Saunier M, Tinoco L, et al; HPV VVAP study group. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer. 2014;50(16):2846-2854
6. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24(suppl 3):S3, 35-41
7. Petrosky E, Bocchini JA Jr, Hariri S, et al; Centers for Disease Control and Prevention (CDC). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300-304
8. Joura EA, Giuliano AR, Iversen OE, et al; Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711-723
9. Van Damme P, Olsson SE, Block S, et al. Immunogenicity and safety of a 9-valent HPV vaccine. Pediatrics. 2015;136(1). Available at: www.pediatrics.org/cgi/content/full/136/1/e28
10. Castellsagué X, Giuliano AR, Goldstone S, et al. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015;33(48):6892-6901
11. Schilling A, Parra MM, Gutierrez M, et al. Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines. Pediatrics. 2015;136(3). Available at: www.pediatrics.org/cgi/content/full/136/3/e563
12. Garland SM, Cheung TH, McNeill S, et al. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine. Vaccine. 2015;33(48):6855-6864
13. Kosalaraksa P, Mehlsen J, Vesikari T, et al. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age. Pediatr Infect Dis J. 2015;34(6):627-634
14. Vesikari T, Brodszki N, van Damme P, et al. A randomized, double-blind, phase iii study of the immunogenicity and safety of a 9-valent human papillomavirus l1 virus-like particle vaccine (V503) versus Gardasil® in 9-15-year-old girls. Pediatr Infect Dis J. 2015;34(9):992-998
15. Chen YH, Gesser R, Luxembourg A. A seamless phase IIB/III adaptive outcome trial: design rationale and implementation challenges. Clin Trials. 2015;12(1):84-90
16. Luxembourg A, Brown D, Bouchard C, et al. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Hum Vaccin Immunother. 2015;11(6):1313-1322
17. GARDASIL. EPAR-Scientific discussion 05/10/2006. Available at: http://www.ema. europa. eu/docs/en-GB/document-library/EPAR--Scientific-Discussion/human/000703/WC500021140.pdf. Accessed March 21, 2016
18. Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J. 2010;29(2):95-101
19. European Medicines Agency. Review concludes evidence does not support that HPV vaccines cause CRPS or POTS. 2015. Available at: http://www.ema. europa. eu/ema/index. jsp? curl=pages/news-and-events/news/2015/11/news-detail-002429. jsp& mid=WC0b01ac058004d5c1. Accessed November 29, 2015
20. Wilcox AJ, Weinberg CR, O'Connor JF, et al. Incidence of early loss of pregnancy. N Engl J Med. 1988;319(4):189-194
21. Wilcox AJ, Baird DD, Weinberg CR. Time of implantation of the conceptus and loss of pregnancy. N Engl J Med. 1999;340(23):1796-1799
22. Lohstroh PN, Overstreet JW, Stewart DR, et al. Secretion and excretion of human chorionic gonadotropin during early pregnancy. Fertil Steril. 2005;83(4):1000-1011
23. García-Enguídanos A, Calle ME, Valero J, Luna S, Domínguez-Rojas V. Risk factors in miscarriage: a review. Eur J Obstet Gynecol Reprod Biol. 2002;102(2):111-119
24. Garland SM, Hernandez-Avila M, Wheeler CM, et al; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-1943
25. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19): 1915-1927
26. Garland SM, Ault KA, Gall SA, et al; Quadrivalent Human Papillomavirus Vaccine Phase III Investigators. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol. 2009;114(6):1179-1188
27. Hobbs CA, Cleves MA, Simmons CJ. Genetic epidemiology and congenital malformations: from the chromosome to the crib. Arch Pediatr Adolesc Med. 2002;156(4):315-320
28. Hollier LM, Leveno KJ, Kelly MA, MCIntire DD, Cunningham FG. Maternal age and malformations in singleton births. Obstet Gynecol. 2000;96(5 Pt 1):701-706
29. Luxembourg A, Bautista O, Moeller E, Ritter M, Chen J. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine. Contemp Clin Trials. 2015;42:18-25
30. Moreira ED Jr, Palefsky JM, Giuliano AR, et al. Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-likeparticle vaccine in older adolescents and young adults. Hum Vaccin. 2011;7(7):768-775
31. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302(7):750-757
32. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011;29(46):8279-8284
33. Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med. 2012;271(2): 193-203
34. Klein NP, Hansen J, Chao C, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med. 2012;166(12):1140-1148
35. Macartney KK, Chiu C, Georgousakis M, Brotherton JM. Safety of human papillomavirus vaccines: a review. Drug Saf. 2013;36(6):393-412
36. Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013;347:f5906
37. Grimaldi-Bensouda L, Guillemot D, Godeau B, et al; PGRx-AID Study Group. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2014;275(4):398-408
38. Scheller NM, Pasternak B, Svanström H, Hviid A. Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism. JAMA. 2014;312(2):187-188
39. Scheller NM, Svanström H, Pasternak B, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015;313(1):54-61
40. Vichnin M, Bonanni P, Klein NP, et al. An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015. Pediatr Infect Dis J. 2015;34(9):983-991
41. Dana A, Buchanan KM, Goss MA, et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol. 2009;114(6):1170-1178
42. Goss MA, Lievano F, Buchanan KM, Seminack MM, Cunningham ML, Dana A. Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine. Vaccine. 2015;33(29):3422-3428